Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran

Respiratory Research

Volumn 7, Issue , 2006, Pages

  Ochs, Matthias ^a,b   Schüttler, Markus ^b   Stichtenoth, Guido ^c   Herting, Egbert ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; LUNG SURFACTANT; PORACTANT; BIOLOGICAL PRODUCT; PHOSPHOLIPID;

ARTICLE; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; LAMELLAR BODY; LUNG ALVEOLUS SURFACE TENSION; MECONIUM; MECONIUM ASPIRATION; NEWBORN; QUANTITATIVE ANALYSIS; SAMPLING; STEREOLOGY; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DRUG ANTAGONISM; SURFACE TENSION;

BIOLOGICAL PRODUCTS; DEXTRANS; HUMANS; INFANT, NEWBORN; MECONIUM; MICROSCOPY, ELECTRON, TRANSMISSION; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 33745700411     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-7-86     Document Type: Article

References (52)

1. Notter RH: Lung surfactants. Basic science and clinical applications. Lung biology in health and disease Volume 149. New York: Marcel Dekker; 2000.
2. McCormack FX, Whitsett JA: The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002, 109:707-712.
3. Wright JR: Pulmonary surfactant: a front line of lung host defense. J Clin Invest 2003, 111:1453-1455.
4. Seeger W, Grube C, Günther A, Schmidt R: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993, 6:971-977.
5. Günther A, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W: Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in large surfactant aggregates. Am J Respir Crit Care Med 1999, 159:244-251.
6. Hawgood S: Surfactant: composition, structure, and metabolism. In The lung. Scientific foundations 2nd edition. Edited by: Crystal RG, West JB, Weibel ER, Barnes PJ. Philadelphia:Lippincott-Raven; 1997:557-571.
7. Ochs M, Johnen G, Müller KM, Wahlers T, Hawgood S, Richter J, Brasch F: Intracellular and intraalveolar localization of surfactant protein A (SP-A) in the parenchymal region of the human lung. Am J Respir Cell Mol Biol 2002, 26:91-98.
8. Lewis JF, Novick RJ, Veldhuizen RAW: Surfactant in lung injury and lung transplantation Austin: RG Landes; 1997.
9. Ikegami M, Jobe AH: Surfactant protein metabolism in vivo. Biochim Biophys Acta 1998, 1408:218-225.
10. Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W: Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001, 2:353-364.
11. Clark DA, Nieman GF, Thompson JE, Paskanik AM, Rokhar JE, Bredenberg CE: Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr 1987, 110:765-770.
12. Moses D, Holm BA, Spitale P, Liu MY, Enhorning G: Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991, 164:477-481.
13. Sun B, Curstedt T, Robertson B: Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 1993, 82:182-189.
14. Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A: Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997, 100:998-1003.
15. Kakinuma R, Shimizu H, Ogawa Y: Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant. Eur J Pediatr 2002, 161:31-36.
16. Walther FJ: Surfactant therapy for neonatal lung disorders other than respiratory distress syndrome. In Surfactant therapy for lung disease. Lung biology in health and disease Volume 84. Edited by: Robertson B, Taeusch HW. New York: Marcel Dekker; 1995:461-476.
17. Robertson B, Johansson J, Curstedt T: Synthetic surfactants to treat neonatal lung disease. Mol Med Today 2000, 6:119-124.
18. Taeusch HW: Treatment of acute (adult) respiratory distress syndrome. The holy grail of surfactant therapy. Biol Neonate 2000, 77(suppl 1):2-8.
19. Wiswell TE: Expanded uses of surfactant therapy. Clinics Perinatol 2001, 28:695-711.
20. Curley AE, Halliday HL: The present status of exogenous surfactant for the newborn. Early Hum Dev 2001, 61:67-83.
21. Merrill JD, Ballard RA: Pulmonary surfactant for neonatal respiratory disorders. Curr Opin Pediatr 2003, 15:149-154.
22. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B: Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001, 50:44-49.
23. Bae CW, Takahashi A, Chida S, Sasaki M: Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998, 44:187-191.
24. Taeusch HW, Lu KW, Goerke J, Clements JA: Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999, 159:1391-1395.
25. Tashiro K, Kobayashi T, Robertson B: Dextran reduces surfactant inhibition by meconium. Acta Paediatr 2000, 89:1439-1445.
26. Tashiro K, Cui XG, Kobayashi T, Curstedt T, Robertson B: Modified protocols for surfactant therapy in experimental meconium aspiration syndrome. Biol Neonate 2003, 83:49-56.
27. Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen WM, Ohmura S, Yamamoto K: Dextran restores albumin-inhibited surface activity of pulmonary surfactant. J Appl Physiol 1999, 86:1778-1784.
28. Lu JJ, Cheung WWY, Yu LMY, Policova Z, Li D, Hair ML, Neumann AW: The effect of dextran to restore the activity of pulmonary surfactant inhibited by albumin. Respir Physiol Neurobiol 2002, 130:169-179.
29. Cui XG, Tashiro K, Matsumoto H, Tsubokawa Y, Kobayashi T: Aerosolized surfactant and dextran for experimental acute respiratory distress syndrome caused by acidified milk in rats. Acta Anaesthesiol Scand 2003, 47:853-860.
30. Taeusch HW, de la Serna JB, Perez-Gil J, Alonso C, Zasadzinski JA: Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: experimental. Biophys J 2005, 89:1769-1779.
31. Dargaville PA, Morley CJ: Overcoming surfactant inhibition with polymers. Acta Paediatr 2000, 89:1397-1400.
32. Lewis JF, Veldhuizen R: The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 2003, 65:613-642.
33. Fehrenbach H, Brasch F, Uhlig S, Weisser M, Stamme C, Wendel A, Richter J: Early alterations in intracellular and alveolar surfactant of the rat lung in response to endotoxin. Am J Respir Crit Care Med 1998, 157:1630-1639.
34. Ochs M, Nenadic I, Fehrenbach A, Albes JM, Wahlers T, Richter J, Fehrenbach H: Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999, 160:718-724.
35. Ochs M, Fehrenbach H, Nenadic I, Bando T, Fehrenbach A, Schepelmann D, Albes JM, Wahlers T, Richter J: Preservation of intraalveolar surfactant in a rat lung ischaemia/reperfusion injury model. Eur Respir J 2000, 15:526-531.
36. Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, Poets CF: Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000, 162:1524-1533.
37. Schmiedl A, Krug N, Hohlfeld JM: Influence of plasma and inflammatory proteins on the ultrastructure of exogenous surfactant. J Electron Microsc 2004, 53:407-416.
38. Fehrenbach H, Ochs M: Studying lung ultrastructure. In Methods in pulmonary research Edited by: Uhlig S, Taylor AE. Basel: Birkhäuser; 1998:429-454.
39. Howard CV, Reed MG: Unbiased stereology. Three-dimensional measurement in microscopy 2nd edition. Oxford: Bios; 2005.
40. Enhorning G: Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977, 43:198-203.
41. Robertson B, Taeusch HW, (Eds): Surfactant therapy for lung disease. Lung biology in health and disease Volume 84. New York: Marcel Dekker; 1995.
42. Clements JA, Avery ME: Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998, 157:S59-S66.
43. Greenough A: Expanded uses of surfactant replacement therapy. Eur J Pediatr 2000, 159:635-640.
44. Amato M, Schürch S, Grunder R, Bachofen H, Burri P: Influence of bilirubin on surface tension properties of lung surfactant. Arch Dis Child 1996, 75:F191-F196.
45. Schrama AJJ, de Beaufort AJ, Sukul YRM, Jansen SM, Poorthuis BJHM, Berger HM: Phospholipase A2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study. Acta Paediatr 2001, 90:412-416.
46. Zasadzinski JA, Alig TF, Alonso C, de la Serna JB, Perez-Gil J, Taeusch HW: Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: theory. Biophys J 2005, 89:1621-1629.
47. Yukitake K, Brown CL, Schlueter MA, Clements JA, Hawgood S: Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995, 37:21-25.
48. Strayer DS, Herting E, Sun B, Robertson B: Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Am J Respir Crit Care Med 1996, 153:1116-1122.
49. 2. J Immunol 2003, 171:995-1000.
50. Holm BA, Waring AJ: Designer surfactants. The next generation in surfactant replacement. Clinics Perinatol 1993, 20:813-829.
51. Lu KW, Goerke J, Clements JA, Taeusch HW: Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 2005, 58:206-210.
52. Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E: Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 2006, 59:407-411.